SAFEs and Convertible Notes: Early-Stage Funding Instruments

What problem do SAFEs and convertible notes solve?

Setting a valuation for a very early startup is genuinely difficult and often counterproductive. With little revenue, an unproven product, and an uncertain market, any valuation is largely guesswork, and negotiating one can be slow, contentious, and distracting at exactly the moment a founder needs to move fast and stay focused. SAFEs, which stands for simple agreements for future equity, and convertible notes were created to sidestep this problem by letting a startup raise money now while deferring the valuation question to a later, more informed moment, typically the next priced funding round.

The mechanism is straightforward in concept: an investor gives the company money today in exchange for the right to receive equity later, when a priced round sets an actual valuation. Instead of buying shares at a price agreed now, the investor’s money converts into shares at that future round, usually on favourable terms that reward them for investing early. This lets the company raise capital quickly, with light paperwork and low legal cost, and lets early investors back the company without either side having to pretend they can value it precisely today.

The difference between the two instruments is largely technical. A convertible note is structured as a loan that converts into equity, carrying an interest rate and a maturity date, which in principle means it could become repayable if no priced round occurs. A SAFE is not debt; it is simply an agreement to issue equity in the future, with no interest or maturity, which makes it simpler and more founder-friendly. SAFEs have become very common at the earliest stages for this reason, though convertible notes remain in use and the underlying logic of both is the same: money now, equity later, on preset terms.

How do valuation caps and discounts work?

Because early investors take more risk than those who come later, SAFEs and notes reward them through two main mechanisms: the valuation cap and the discount. The valuation cap sets a maximum company valuation at which the investor’s money will convert, regardless of how high the actual priced-round valuation turns out to be. If the company does well and raises its next round at a valuation above the cap, the early investor still converts as if the valuation were the lower cap, meaning they receive more shares for their money than the new investors do. The cap protects early backers from being penalised for the very success they helped enable.

The discount works alongside or instead of the cap, giving the early investor a percentage reduction on the price paid by the new investors in the priced round. A twenty percent discount, for example, means the early money converts at eighty percent of the round’s price, again rewarding the investor with more shares per dollar than those investing later. Some instruments use both a cap and a discount, with the investor receiving whichever gives them the better outcome, which is more generous to the investor and more dilutive to the founders.

For founders, these terms are the real substance of the negotiation, far more than the headline amount raised. A low valuation cap is attractive to investors because it guarantees them a larger share when conversion happens, but it is costly to founders for exactly the same reason, since it means giving away more equity. Founders sometimes focus on raising a large sum at a friendly-sounding cap without fully appreciating that the cap, not the amount, drives how much of the company they will ultimately surrender. Understanding precisely how the cap and discount will translate into shares at conversion is essential to knowing what a given instrument really costs.

What is the hidden danger of raising on these instruments?

The great convenience of SAFEs and notes, that they are fast and easy to issue, is also the source of their characteristic danger. Because raising a small amount on a new SAFE is so simple, founders sometimes raise repeatedly on a series of instruments, each at its own cap, without keeping a running tally of what they will all become when they convert together at the next priced round. The dilution from each individual instrument seems modest, but the cumulative effect of many of them converting at once can be far larger than the founder intuitively expected, producing an unpleasant surprise precisely when the priced round forces a reckoning.

This stacking problem is compounded by the fact that the instruments convert at their caps, which on a successful company are usually well below the priced-round valuation, so the early money buys a disproportionately large number of shares. A founder who has raised several rounds of SAFEs at low caps may discover, when the priced round arrives, that the combined conversion consumes a much bigger slice of the company than the headline amounts suggested, leaving the founders with less ownership than they assumed they had retained. The lightness of each transaction obscures the weight of their sum.

The discipline that prevents this is simply to track the cumulative effect continuously rather than treating each instrument in isolation. Founders who maintain a model showing what their cap table will look like after all outstanding instruments convert, updated each time a new one is issued, keep their eventual ownership in view and can decide deliberately how many more they are willing to raise. This is not a reason to avoid SAFEs and notes, which remain excellent tools for early-stage fundraising, but a reason to use them with the same care for cumulative dilution that any responsible management of the cap table requires.

When should founders use these instruments, and when not?

SAFEs and convertible notes are well suited to the earliest stages, when setting a valuation is genuinely premature and the priority is to raise a modest amount quickly to reach the next milestone. For pre-seed and seed-stage companies raising from angels and early funds, these instruments offer real advantages: speed, low cost, and the ability to bring in money without a contentious valuation negotiation. Used for their intended purpose, raising early capital to get to a priced round, they serve founders well and have become the standard tool for good reason.

They become less appropriate as the amounts grow and the company matures toward the point where a real valuation can and should be set. Raising a very large sum on uncapped or high-cap instruments, or relying on them well past the stage where a priced round would be sensible, can store up complexity and dilution that a properly negotiated priced round would have made explicit. At some point the deferral of the valuation question stops being a convenience and starts being an avoidance, and founders are better served by setting a real price and dealing with the cap table clearly.

The sound approach is therefore to treat SAFEs and notes as a deliberate early-stage tool with a clear purpose, used in known quantities and with the cumulative dilution tracked, rather than as an endlessly convenient way to keep raising money without confronting valuation. Founders who understand the caps and discounts, model the conversion, and know how much of the company they are committing across all their outstanding instruments capture the genuine benefits of these tools while avoiding the dilution surprises that catch out those who use them casually. As with every part of fundraising, the instrument is only as good as the founder’s understanding of what it will eventually cost.

How do these instruments fit a startup’s overall funding strategy?

SAFEs and convertible notes are best understood not as standalone events but as the early chapters of a funding story that usually leads to a priced round, and founders who plan the whole arc use them more wisely. The instruments are tools for getting from an idea to the point where a real valuation makes sense, and the amount raised on them, the caps agreed, and the number issued should all be chosen with that destination in mind. A founder who raises early money thinking only about the immediate need, without regard to how it will all convert at the eventual priced round, can undermine their position at the very moment the funding story is supposed to pay off.

Sequencing matters within this arc. Raising a sensible amount on early instruments to reach a clear milestone, then converting them cleanly at a priced round once the company can support a genuine valuation, is the intended pattern and it works well. Problems arise when founders use the ease of these instruments to defer the priced round long past the point where it would be appropriate, accumulating layers of instruments at different caps that turn the eventual conversion into a complicated and heavily dilutive event. Knowing when to stop raising on instruments and set a real price is part of using them strategically.

The instruments also interact with the company’s negotiating position over time. Early money raised at a reasonable cap, when the company had little to show, is fair to both sides; but as the company progresses and its prospects improve, continuing to raise at low caps gives away more of the now-more-valuable company than necessary. Founders who track how their company’s value is growing relative to the caps they are agreeing can recognise when the terms that made sense early have become unfavourable, and can move to a priced round that prices the company fairly rather than locking in early-stage terms long after the early stage has passed.

Used within a clear overall strategy, knowing the purpose, tracking the cumulative dilution, and recognising when to transition to a priced round, SAFEs and convertible notes are excellent tools that let startups raise early capital quickly and fairly. Used without that strategy, as an endlessly convenient way to keep money coming in without confronting valuation, they can quietly erode founder ownership and complicate the cap table in ways that surface painfully later. The instrument is sound; what matters is whether the founder uses it as part of a deliberate plan or as a way of avoiding decisions that eventually have to be faced.

Frequently Asked Questions

Frequently Asked Questions